Latest Biotech News

Aragen Biologics introduced CHOMax, an integrated CHO cell‑line development and early GMP manufacturing platform designed to move antibody programs from DNA to IND‑enabling clinical supply in...

Liquid‑biopsy firm Syantra launched a multicenter, 2,000‑subject study to support clinical implementation and market access for Onco‑ID Breast, its whole‑blood mRNA assay for early breast cancer...

Eli Lilly agreed to acquire Ventyx Biosciences in a roughly $1.2 billion all‑cash transaction, securing clinical‑stage NLRP3 inhibitor programs and near-term assets aimed at chronic inflammation....

Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million plus royalties, adding the preclinical DBT‑3757 degrader directed at MLLT1 and MLLT3 and Dark Blue’s cancer discovery...

Radiopharmaceutical developer Aktis Oncology completed a Nasdaq IPO that raised about $318 million, marking the first biotech public offering of 2026. The company plans to use proceeds to advance...

Parabilis Medicines closed a $305 million Series F round to advance its Helicon‑peptide platform and push lead candidate zolucatetide toward later‑stage development. The financing, led by major...

AirNexis Therapeutics raised $200 million to acquire global rights to Haisco Pharmaceutical Group’s inhaled PDE3/4 inhibitor (HSK39004, coded AN01) and advance it in COPD outside China. Under the...

Cellares and City of Hope launched a collaboration to evaluate automated manufacturing and QC platforms for City of Hope’s investigational CAR T program targeting glioblastoma multiforme. City of...

Aurora Therapeutics launched with seed funding and a leadership team tied to the ‘Baby KJ’ personalized CRISPR success story, aiming to develop grouped, customizable gene‑editing therapies that...

GSK committed $50 million upfront to license Noetik Discovery’s foundation AI models trained on large spatial biology datasets for non‑small cell lung and colorectal cancer research. The...

EpiBiologics closed a $107 million Series B to advance EPI‑326, a bispecific antibody designed to degrade tumor EGFR via targeted lysosomal routing, into first‑in‑human studies. The Bay Area...

Medipost secured $140 million to support commercialization and regulatory filings for its allogeneic stem cell therapy in the U.S. and Japan. The Seoul‑area company will use the funds to expand...

Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion in cash, closing a deal that transfers clinical-stage NLRP3 inhibitor programs into Lilly’s pipeline. The transaction,...

Merck reportedly entered talks to acquire Revolution Medicines in a deal valued between $28 billion and $32 billion, according to media reports citing unnamed sources. The discussions center on...

Radiopharmaceutical developer Aktis Oncology priced an upsized initial public offering that raised roughly $318 million in gross proceeds, with Eli Lilly taking a $100 million stake as part of the...

Parabilis Medicines closed a $305 million Series F round to accelerate its Helicon peptide platform and advance lead candidate zolucatetide toward later‑stage testing. The financing was led by RA...

EpiBiologics secured $107 million in a Series B round led by GV and J&J’s venture arm to push its antibody‑based protein degraders (EpiTACs) into first‑in‑human studies. The Bay Area startup will...

Immuneering reported updated phase 2a data showing a 64% overall survival rate at one year for atebimetinib, its oral MEK inhibitor, combined with modified gemcitabine/nab‑paclitaxel as first‑line...

Cellares and City of Hope signed a collaboration to evaluate automated, high‑throughput manufacturing and QC for a CAR‑T program targeting glioblastoma multiforme. City of Hope will test Cellares’...

OpenAI introduced ChatGPT for Healthcare, an enterprise offering to integrate the ChatGPT platform into hospital and health‑system workflows. The product is positioned to support clinical...